UBI集團訊息
United BioPharma to establish industrial protein drug manufacturing process via ICP program
United BioPharma’s parent company, UBIAsia responded that both the company and the biotechnology industry lacks tons – scale protein drug manufacturing technology and facility. As protein drug manufacturing technology is of high economic value, the Biotechnology and Pharmaceutical Industries Office of MOEA recommended to IDB that Taiwan should sponsor and implement an Industrial Cooperation Program (ICP) sponsored by IDP totransfer such technologies from US or EU biopharmaceutical companies.
Through critical evaluation, as a result of the company’s capabilities, United BioPharma was selected to be the recipient of the state-of-the -art antibody drug bioprocess and manufacturing technology.
In 2016, UBP sent a seed team to GE Healthcare in the US to train in 500-2000L process technology. UBP’s new protein drug manufacturing facility program which is an investment up to NT$1.3 billion, is about to be completed and to be operated in 2017. The 2000L process technology will be transferred from GE Healthcare to UBP and to be implemented in the new plant. The new plant will be installed with 2 x 2000L single use process production line at the first stage. There is more space reserved that allows to accommodate up to 12 x 2000L production lines within this new plant. The UBP’s new biopharmaceutical plant will become an important base of protein drug manufacturing with high quality in Asia. UBP will also be positioned as a leader in the biopharmaceutical industry of Asia in the coming years.
About UBP (6471)
UBP was established in October 2013 as a monoclonal antibody business spinoff from United Biomedical, Inc., Asia, and is strategically partnering with Formosa Plastics Group. UBO has an integrated monoclonal antibody drug developing platform, and focuses on development, manufacturing, and marketing of innovative monoclonal antibody drugs and biosimilars. With a spirit of “innovation and practicality,” UBP is dedicated to addressing unmet medical needs, thereby improving the health of mankind and economic advancement of Taiwan. For more information, please visit http://www.unitedbiopharma.com
United BioPharma Forward-Looking Statements
The information in this press release should be considered accurate only as of the date of the release. UBP has no intention of updating and specifically disclaims any duty to update the information in this press release. The press release may contain forward-looking statements involving risks and uncertainties and UBP’s actual results may differ materially from those in the forward-looking statements.